Blog Posts - Diabetic Macular Edema



Alimera Sciences (ALIM) Sustained Release Intravitreal Implant Gets Marketing Authorization In Italy for the Treatment of Chronic Diabetic Macular Edema

Alimera Sciences, Inc. (ALIM) According to the 2014 National Diabetes Statistics Report, 29.1 million people or 9.3% of the population in the United States have diabetes. People with diabetes are at an increased risk for developing eye problems. One...
by PennyOmega.com on Jun 24, 2014

Bevacizumab – Treatment For Diabetic Macular Edema

According to a study published Online First by Archives of Ophthalmology, bevacizumab appears to be more effective at treating diabetic macular edema (swelling of the retina) than macular laser therapy… <a href="http://www.medicalnewsto...

Diabetes Signs and Symptoms For Eyes

Diabetes is the leading cause of blindness and that is a major reason for concern because it is largely preventable. When blood sugar level stay high (8mmol/l plus) for long periods of time, it can cause damage to the small … Continue reading &...
by Diabetes Away on Sep 19, 2011

NICE Turns Down Lucentis (Ranibizumab) For Diabetic Macular Edema Treatment, UK

NICE (National Institute for Clinical Excellence) in the UK has decided not to recommend Lucentis (ranibizumab) for diabetic macular edema (British spelling: oedema) treatment. NICE approves or turns down treatments that will be covered by the NHS (N...

Actos And Avandia Use Associated With Diabetic Macular Edema, Which Can Lead To Blindness

New UK Study Found Three To Six Times Increased Risk Of Developing This Retinal Eye Disease Side Effect (Posted by Tom Lamb at DrugInjuryWatch.com) A study presented at the American Diabetes Association’s annual meeting in San Diego on June 26, 201...
by Drug Injury Watch on Jun 27, 2011

pSivida Announces Resubmission Of New Drug Application For ILUVIEN(R)

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the...

Study Demonstrates Benefits Of MicroPulse™ Photocoagulation Over Current Standard Laser Treatment Of Diabetic Macular Edema

IRIDEX Corporation (Nasdaq: IRIX) announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX laser...

PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME™ Study of ILUVIEN for...

Molecular Partners Reports Positive Results From Its First Clinical Studies

Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A. The DARPin molecule was shown to be safe and we...

Second Lucentis Phase III Study Meets Primary Endpoint For Improved Vision In Patients With Diabetic Macular Edema (DME)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the second of two Phase III trials evaluating Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME) met its primary endpoint… <a...

In A Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard Of Care In Patients With Diabetic Macular Edema At 12 Months

Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the s...

Lucentis Phase III Study Meets Primary Endpoint For Improving Vision In Patients With Diabetic Macular Edema (DME)

Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint...

Diabetic Retinopathy – Treatment For Diabetic Eye Disease

There are various treatments available for the different manifestations of diabetic retinopathy. It used to be that laser treatment, of one form or the other, was the treatment of choice. Nowadays, there are intraocular injections of steroids, anti-V...


Trending Topics

Close